Poseida in the News

Explore recent media coverage of Poseida and find out how we are creating the next wave of cell and gene therapies with the capacity to cure.

Targeting Solid Tumors with Cell Therapies

Cell & Gene | March 29, 2022

Building the Next-Generation of Cell and Gene Therapies

The Bio Report Podcast | March 23, 2022

Interview with Poseida CEO Mark Gergen

Tacos and Tech Podcast | March 8, 2022

Poseida taps former Novartis VP as president of gene therapy

Fierce Biotech | February 22, 2022

Memory T Cell CAR T Therapy Showcases Anti-Tumor Activity
in Resistant Prostate Cancer

CGT Live | February 17, 2022

FDA clears IND application for allogeneic CAR-T to treat certain solid tumors

Healio | December 22, 2021

Poseida’s CAR T-Cell Therapy IND Accepted for Solid Tumors

CGT Live | December 22, 2021

20 Years in the Making: Reflections and Predictions

PharmaVOICE | November/December 2021

Considering Manufacturing and Commercial Advantages,
Poseida Makes Strategic Shift Towards Allogeneic CAR-T Products

Gene Online | November 10, 2021

Interview with Dr. Eric Ostertag, Poseida Therapeutics

Drug Target Review Podcast | November 1, 2021

Close to the Edge Interview with Poseida CEO Eric Ostertag

GEN | October 27, 202

Poseida CEO Eric Ostertag Interview

Talking Biotech Podcast | October 23, 2021

The Top 25 Women Leaders in Biotechnology of 2021

The Healthcare Technology Report | October 19, 2021

With Up-to-$3.6B Poseida Collaboration, Takeda Doubles Down on Gene Therapy

GEN | October 14, 2021

Takeda broadens gene therapy scope, turns to Poseida for non-viral approach

MedCity News | October 12, 2021  

Poseida Therapeutics, Takeda Pharmaceutical in Research, License Pact >PSTX

MarketWatch | October 12, 2021 

Billions club: Takeda taps Poseida for 2nd $1B-plus gene therapy pact in 2 weeks

Fierce Biotech | October 12, 2021

Takeda takes aim at a biotech’s gene therapy work

BioPharma Dive | October 12, 2021 

eBook: CAR-T Cell Therapy — Mitigating Clinical and Bioprocess Limitations

BioProcess International | September 30, 2021

Building A DNA Delivery System
With Poseida Tx CEO Eric Ostertag, M.D., Ph.D.

Business of Biotech Podcast | September 27, 2021

Q&A: Mark Gergen, Poseida Therapeutics

Pharmaceutical Executive | September 8, 2021

Getting Closer to Single-Treatment Cures at Poseida Therapeutics

CRISPR Medicine News | September 6, 2021

Novel CAR T-Cell Therapy P-PSMA-101 Shows Promise in mCRPC

Targeted Oncology | September 1, 2021

Poseida’s CAR-T Cell Therapy for Prostate Cancer Shows Promising Durable Response in Phase 1

CGT Live | September 1, 2021

P-PSMA-101 Elicits Encouraging Responses in Metastatic Castration-Resistant Prostate Cancer

OncLive | September 1, 2021

Poseida Therapeutics: Creating the Next Wave of Cell & Gene Therapies With the Capacity to Cure

Drug Development & Delivery | September 2021

Poseida Presents Encouraging Preliminary Data for Autologous CAR-T Candidate Against Solid Tumors

GeneOnline News | August 31, 2021

FDA clears IND application for BCMA-directed allogenic CAR-T to treat multiple myeloma

Healio (Hem/Onc Today) | August 30, 2021

The Top 100 Healthcare Technology Companies of 2021

The Healthcare Technology Report | August 24, 2021